Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients-Reference-Cited by-同舟云学术

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

Published:2017-09 Issue: Volume:83 Page:106-115
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Cascinu Stefano,Rosati Gerardo,Nasti Guglielmo,Lonardi Sara,Zaniboni Alberto,Marchetti Paolo,Leone Francesco,Bilancia Domenico,Iaffaioli Rosario Vincenzo,Zagonel Vittorina,Giordano Monica,Corsi Domenico C.,Ferraú Francesco,Labianca Roberto,Ronzoni Monica,Scartozzi Mario,Galli Francesca,Cascinu Stefano,Rosati Gerardo,Bilancia Domenico,Nasti Guglielmo,Iaffaioli Rosario Vincenzo,Lonardi Sara,Zagonel Vittorina,Zaniboni Alberto,Marchetti Paolo,Romiti Adriana,Leone Francesco,Aglietta Massimo,Giordano Monica,Corsi Domenico C.,Ferraú Francesco,Labianca Roberto,Mosconi Stefania,Ronzoni Monica,Gianni Luca,Rulli Eliana,Poli Davide,Galli Francesca,Torri Valter,De Simone Irene,Galli Fabio,Pasini Felice,Rangoni Giovanni,Venezia Raffaele,Sozzi Pietro,Nuzzo Antonio,Berardi Rossana,Frontini Luciano,Rota Silvia,Cozzi Lorena

Funder

AIFA

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Colorectal cancer statistics;Siegel;CA: Cancer J Clin,2014

2. First line chemotherapy for mCRC-a review and evidence-based algorithm;Cremolini;Nat Rev Clin Oncol,2015

3. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

4. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy refractory metastatic colorectal cancer: a retrospective consortium analysis;De Roock;Lancet Oncol,2010

5. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial;Koopman;Lancet,2007

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors;Critical Reviews in Oncology/Hematology;2024-06

2. Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study);Clinical Colorectal Cancer;2024-06

3. Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA);Digestive and Liver Disease;2023-08

4. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer;Frontiers in Oncology;2023-02-02

5. The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status;Cancers;2022-11-01